このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

腎移植の低リスクレシピエントにおける免疫モニタリングと CNI 中止

腎移植の低リスクレシピエントにおける免疫モニタリングとカルシニューリン阻害剤(CNI)の中止

The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn. In addition, this research study will evaluate whether reducing immunosuppression can decrease some of these side effects while still preventing rejection of the kidney.

調査の概要

詳細な説明

Kidney transplantation is a treatment option for people with kidney disease. However, there is still much to learn about how to best care for the transplanted kidney and keep it functioning for a long time. Transplant recipients take immunosuppression (anti-rejection) drugs to prevent their body from rejecting the new kidney. These drugs are used to prevent the immune system from attacking the transplanted kidney. All anti-rejection medications have unwanted side effects. The purpose of this study is to evaluate the safety of slowly removing tacrolimus, a CNI.

研究の種類

介入

入学 (実際)

52

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • California
      • Los Angeles、California、アメリカ、90055
        • University of California Los Angeles
    • Connecticut
      • New Haven、Connecticut、アメリカ、06520-8029
        • Yale University School of Medicine
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02115
        • Brigham & Women's Hospital
    • Michigan
      • Ann Arbor、Michigan、アメリカ、48109
        • University of Michigan Hospital
    • Missouri
      • St Louis、Missouri、アメリカ、63110
        • Washington University
    • New York
      • New York、New York、アメリカ、10029
        • Mount Sinai School of Medicine
    • Ohio
      • Cleveland、Ohio、アメリカ、44195
        • Cleveland Clinic Foundation
      • Cleveland、Ohio、アメリカ、44106-5048
        • University Hospitals of Cleveland
    • Texas
      • Houston、Texas、アメリカ、77030
        • The Methodist Hospital
    • Manitoba
      • Winnipeg、Manitoba、カナダ、R3A IR9
        • Health Sciences Centre
    • Ontario
      • Toronto、Ontario、カナダ、M5G 2M1
        • Toronto General Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

INCLUSION CRITERIA -

Initial Enrollment/Screening: Patients who meet all of the following criteria are eligible for enrollment as study subjects:

  • Subject must be able to understand and provide written informed consent;
  • Primary living-donor (related or unrelated) kidney transplant recipients;
  • Peak flow-based PRAs for class I and class II <30%(performed by local center);
  • Current (within 8 weeks prior to transplantation) flow-based PRAs for class I and class II <30% (performed by local center);
  • No donor specific antibody by flow solid phase method on the peak PRA serum (if serum available), or on the current PRA serum (within 8 weeks prior to transplantation) performed by central core laboratory. If the sera for the peak PRA is not available, then only the current PRA serum will be tested;
  • Negative T-cell and B-cell crossmatch by flow cytometry (performed by local center);
  • Female subjects of childbearing potential must have a negative pregnancy test (urine or serum) upon study entry;
  • Female and male subjects with reproductive potential must agree to use FDA approved methods of birth control while participating in the study.

Inclusion Criteria for Randomization:

Participants who meet all of the following criteria are eligible for randomization:

  • No history of acute rejection episodes;
  • The pre-randomization protocol biopsy should confirm no rejection, including borderline rejection (based on the central pathology read);
  • No donor specific antibody as detected by flow solid phase method (performed by the central core laboratory).

EXCLUSION CRITERIA -

Initial Enrollment/Screening:

Participants who meet any of these criteria are not eligible for enrollment as study subjects:

  • Recipient of multiple organ transplants;
  • Prior history of organ transplantation;
  • Deceased-donor source;
  • Any condition that would preclude protocol biopsies;
  • HLA identical recipients;
  • Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;
  • Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;
  • Inability or unwillingness to comply with study protocol;
  • Use of investigational drugs within 4 weeks of study entry and for the duration of the study;
  • Recent recipient of any licensed or investigational live attenuated vaccine(s) within two months of prior to study entry.

Exclusion Criteria for Randomization:

Participants who meet any of these criteria are not eligible for randomization:

  • Subjects who receive less than 4.5mg/kg of Rabbit ATG (Thymoglobulin®) induction therapy;
  • Subjects who test positive for BKV by PCR in the blood at 6 months post-transplant;
  • Any condition that would preclude protocol biopsies;
  • Currently breast-feeding or plans to become pregnant during the timeframe of the study follow up period;
  • Any condition that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements;
  • Inability or unwillingness of a subject to give written informed consent or comply with study protocol;
  • Use of investigational drugs within 4 weeks of study entry and for the duration of the study;
  • Subjects who receive less than 1500 mg daily of Mycophenolate Mofetil (CellCept®) or equivalent.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Tacrolimus (CNI) Withdrawal

Subjects randomized (2:1) to tacrolimus (CNI) withdrawal.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test are randomized (2:1) to tacrolimus (CNI) withdrawal.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.

Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal.

他の名前:
  • サイモグロブリン®
  • ミコフェノール酸モフェチル
  • セルセプト®
  • ATG導入、タクロリムス(CNI)、MMF、プレドニゾン、その後CNI離脱
  • ウサギ抗胸腺細胞グロブリン (RATG)
  • カルシニューリン阻害剤 (CNI)

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.

他の名前:
  • サイモグロブリン®
  • ミコフェノール酸モフェチル
  • セルセプト®
  • ウサギ抗胸腺細胞グロブリン (RATG)
  • カルシニューリン阻害剤 (CNI)
  • ATG誘導、タクロリムス(CNI)、MMF、プレドニゾン
アクティブコンパレータ:Standard Immunosuppressive Therapy

Subjects randomized to standard immunosuppressive therapy, without subsequent tacrolimus (CNI) withdrawal.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a standard immunosuppressive regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus. Tacrolimus (CNI) withdrawal does not occur.

Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.

他の名前:
  • サイモグロブリン®
  • ミコフェノール酸モフェチル
  • セルセプト®
  • ウサギ抗胸腺細胞グロブリン (RATG)
  • カルシニューリン阻害剤 (CNI)
  • ATG誘導、タクロリムス(CNI)、MMF、プレドニゾン

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants With Incremental IF/A Scores >2 at 24 Months Post-Randomization
時間枠:IF/TA scores on protocol biopsies obtained at 24 months post-randomization will be compared to those obtained at the time of implantation for this measurement.

The investigators were not able to assess this outcome, the effect of the intervention on interstitial fibrosis/tubular atrophy (IF/TA; on a 2-year graft biopsy) due to the study's premature termination by the Data Safety Monitoring Board (DSMB) because of absence of equipoise on the basis of predetermined stopping rules.

IF/TA scores on protocol biopsies obtained at 24 months post-randomization will be compared to those obtained at the time of implantation for this measurement.

二次結果の測定

結果測定
メジャーの説明
時間枠
Estimated GFR Using the Chronic Kidney Disease Epidemiology (CKD-EPI) Equation
時間枠:6 months post-transplantation, 24 months post-transplantation

Estimated glomerular filtration rate (eGFR) is a test to measure the level of kidney function. In this measure, the effects of tacrolimus withdrawal on long-term kidney function was assessed by comparing absolute 24 month eGFR (18 months post-randomization) and change in eGFR from 6 to 24 months (randomization to 18 months randomization). Lower numbers indicate poorer kidney function

6 months post-transplantation, 24 months post-transplantation
Incidence of Acute Rejection
時間枠:6 to 18 months post-randomization

Acute renal allograft rejection is defined as histological reading of borderline or greater determined by the local pathology laboratory. Participants suspected of having a rejection episode on the basis of clinical signs, symptoms, or on the basis of laboratory tests, had a renal ultrasound and underwent a renal transplant biopsy. Any detection of acute cellular rejection or acute humoral rejection resulted in participants in the 'Randomized to Tacrolimus Withdrawal' group to be restarted on tacrolimus and followed per the reduced follow-up schedule of events.

6 to 18 months post-randomization
Allograft Survival Rate
時間枠:6 to 18 months post-randomization

Allograft survival is defined as participants who did not need to be re-transplanted or placed on dialysis due to the failure of their allograft transplantation during the course of this study.

6 to 18 months post-randomization
Participant Survival Rate
時間枠:6 to 18 months post-transplantation

Number of participants who did not die within the course of this study.

6 to 18 months post-transplantation
Percentage of Participants With New Donor Specific Antibodies (DSAs)
時間枠:6 to 18 months post-randomization

Donor specific antibodies are antibodies that are directed against antigens expressed on donor organs. These antibodies can result in an immune attack on the transplanted organ, increasing risk of graft loss and/or rejection.

6 to 18 months post-randomization
Percentage of Participants With Donor-Specific Memory Using Elispot
時間枠:6 to 18 months post-randomization

This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.

6 to 18 months post-randomization
Percentage of Participants in the Experimental Arm Off Tacrolimus
時間枠:18 months post-randomization

Participants in the 'Randomized to Tacrolimus Withdrawal' group were considered fully withdrawn once they no longer received any doses of tacrolimus. Participants met this endpoint if they did not resume taking tacrolimus as of 18 months post randomization with stable allograft function and without rejection of donor-specific antibodies.

18 months post-randomization
Incremental Change in IF/TA Scores
時間枠:6 to 18 months post-transplant

This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.

6 to 18 months post-transplant
Measurement of Urinary Parameters Before and After Randomization
時間枠:6 months post-transplantation to 18 months post-randomization

This endpoint was unable to be analyzed because the study was terminated early after stopping rules were met.

6 months post-transplantation to 18 months post-randomization

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディチェア:Donald Hricik, MD、University Hospitals Cleveland Medical Center
  • 主任研究者:Peter S. Heeger, MD、Icahn School of Medicine at Mount Sinai

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始

2010年11月1日

一次修了 (実際)

2015年5月1日

研究の完了 (実際)

2015年5月1日

試験登録日

最初に提出

2012年1月20日

QC基準を満たした最初の提出物

2012年1月20日

最初の投稿 (推定)

2012年1月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月24日

QC基準を満たした最後の更新が送信されました

2026年9月22日

最終確認日

2026年9月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する